Gifts of Stock

Learn how to make a gift of stock to the Minneapolis Heart Institute Foundation.

Gifts of publicly traded securities provide a double tax benefit. You avoid a capital gains tax on appreciated securities, and you receive a charitable income tax deduction for the full fair market value of the securities.

How to donate stock

Step 1: Provide your broker with the following information to start the transfer process

Legal name:
Minneapolis Heart Institute Foundation
Attn: Development
920 East 28th Street, Suite 100
Minneapolis, MN 55407

Non-profit status: IRC 501(c)(3) organization
IRS Identification (EIN) #: 41-1426406

Designated broker account:
Firm: UBS Financial Services
681 Lake St E, Suite 354,
Wayzata, MN, 55391
Contact: Andrew Kiernan
Phone: 952-475-9463
Account: #RP05512 DTC: #0221

Step 2: Contact Minneapolis Heart Institute Foundation to notify us of your gift

Contact information:
Minneapolis Heart Institute Foundation Development Office
920 East 28th Street, Suite 100
Minneapolis, MN 55407
Phone: 612-863-3833
Email: donorrelations@mhif.org

Please provide the following information:

  • Name
  • Address
  • Stock name
  • Approximate amount
  • Purpose of gift
Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.